Resolution of Systemic Inflammation in Patients With Recently Decompensated Heart Failure With Reduced Ejection Fraction With and Without Interleukin-1 Blockade by Anakinra.

ABSTRACT:

Background

Decompensated heart failure with reduced ejection fraction (HFrEF) is associated with systemic inflammation that predicts unfavorable outcomes. We aimed to determine whether anakinra, an IL-1 (interleukin-1) blocker, favors inflammation resolution (CRP [C-reactive protein]) and improves peak oxygen consumption (VO₂) in patients with recently decompensated HFrEF.

Methods

We randomized 102 adult patients recently hospitalized for HFrEF and CRP ≥2 mg/L (2:1) to receive anakinra 100 mg subcutaneously daily (n=68) or placebo for 24 weeks (n=34). The primary end point was the peak VO₂ change at 24 weeks. Data are presented as median (Q1, Q3) or number (%).

Results

Of the 102 patients, 84 had primary end point data available (57 treated with

SUBMITTER: Van Tassell BW 

PROVIDER: S-EPMC12747512 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature